肿瘤防治研究2025，Vol.52Issue(2)：110-117,8.DOI:10.3971/j.issn.1000-8578.2025.24.0971
放射性配体疗法在晚期恶性肿瘤中的应用现状及进展
Current Status and Progress of Radioligand Therapy in Advanced Malignant Tumors
邱大胜 1James Nagarajah 2崔殿生 3魏少忠3
作者信息
- 1. 430079 武汉,湖北省肿瘤医院核医学科
- 2. NB6511 奈梅亨,拉德堡德大学医学中心核医学科
- 3. 430079 武汉,湖北省肿瘤医院泌尿肿瘤外科
- 折叠
摘要
Abstract
In 1946,radioactive iodine 131 was first used for the treatment of differentiated thyroid cancer.However,the limitations of early nuclear medicine technology,the lack of specificity,the efficacy of nuclide therapy,and its adverse effects have limited its widespreadly clinical application.In recent years,scientists and clinicians have linked radioisotopes to targeted parts(tumor-specific small molecules,peptides,or antibodies)to develop safe and effective nuclear drugs.Ra-223,Lutathera(lutetium-177),and Pluvicto(177Lu-PSMA-617)have been successfully used in clinical treatment.Radioligand therapy has gradually shown good efficacy in different tumors.This paper focuses on the current situation of the application of therapeutic radioligand drugs in advanced malignant tumors and the latest research results and treatment strategies to achieve more accurate and personalized treatment methods,thereby to improve the curative effect,and reduce adverse reactions.关键词
放射性配体疗法/恶性肿瘤/晚期Key words
Radioligand therapy/Malignancy/Advanced分类
临床医学引用本文复制引用
邱大胜,James Nagarajah,崔殿生,魏少忠..放射性配体疗法在晚期恶性肿瘤中的应用现状及进展[J].肿瘤防治研究,2025,52(2):110-117,8.
